-

West Pharmaceutical Services, Inc. (WST) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of West Pharmaceutical Services, Inc. (“West” or the “Company”) (NYSE: WST) investors concerning the Company’s possible violations of federal securities laws.

IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN WEST PHARMACEUTICAL SERVICES, INC. (WST), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS.

Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at howardsmith@howardsmithlaw.com, by telephone at (215) 638-4847 or visit our website at www.howardsmithlaw.com.

What Happened?

On February 13, 2025, West issued disappointing revenue and earnings forecasts for 2025, attributing it, in part, to Contract Manufacturing headwinds, including the loss of two major continuous glucose monitoring customers. Additionally, West disclosed that its SmartDose wearable injector devices would be “margin dilutive” in 2025 and that it would be “taking steps to improve [its SmartDose] economics, and all options are on the table.”

On this news, West’s stock price fell $123.17, or 38.2%, to close at $199.11 per share on February 13, 2025, thereby injuring investors.

Contact Us To Participate or Learn More:

If you purchased West securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us:

Law Offices of Howard G. Smith,
3070 Bristol Pike, Suite 112,
Bensalem, Pennsylvania 19020,
Telephone: (215) 638-4847
Email: howardsmith@howardsmithlaw.com
Visit our website at: www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
howardsmith@howardsmithlaw.com
www.howardsmithlaw.com

Industry:

Law Offices of Howard G. Smith

NYSE:WST
Release Versions
English

Contacts

Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
howardsmith@howardsmithlaw.com
www.howardsmithlaw.com

More News From Law Offices of Howard G. Smith

Law Offices of Howard G. Smith Encourages Varonis Systems, Inc. (VRNS) Shareholders To Inquire About Securities Fraud Class Action

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Varonis Systems, Inc. (“Varonis” or the “Company”) (NASDAQ: VRNS) common stock between February 4, 2025 and October 28, 2025, inclusive (the “Class Period”). Varonis investors have until March 9, 2026 to file a lead plaintiff motion. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN VARONIS SYSTEMS, INC. (VRNS), CONTACT THE LAW OFFICES OF HOWARD G....

agilon health, inc. (AGL) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of agilon health, inc. (“agilon” or the “Company”) (NYSE: AGL) investors concerning the Company’s possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN AGILON HEALTH, INC. (AGL), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. Contact the Law Offices of Howard G. Smith to discuss your legal rights by email...

Deadline Approaching: Fermi Inc. (FRMI) Shareholders Who Lost Money Urged To Contact Law Offices of Howard G. Smith

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith reminds investors of the upcoming March 6, 2026 deadline to file a lead plaintiff motion in the case filed on behalf of Fermi Inc. (“Fermi” or the “Company”) (NASDAQ: FRMI) investors who purchased: (a) common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the “Registration Statement”) issued in connection with the Company’s October 2025 initial public offering (“IPO” or the “Offering”); a...
Back to Newsroom